IL17A and prostate carcinoma: Indeed, inflammation status, including also the release of inflammatory cytokines such as interleukin (IL)-1, IL-6 and IL-17, has been associated with the development and progression of prostate cancer [7,12,19], and androgens have been reported to alter T-cell immunity [17,20,21].